[1] Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report:primary brain and other central nervous system tumors diagnosed in the United States in 2014-2018[J]. Neuro Oncol, 2021, 23(12 Suppl 2):iii1-105. [2] Alifieris C, Trafalis DT. Glioblastoma multiforme:pathogenesis and treatment[J]. Pharmacol Ther, 2015, 152:63-82. [3] Yamini B. NF-κB, mesenchymal differentiation and glioblastoma[J]. Cells, 2018, 7:125. [4] Bhat KPL, Balasubramaniyan V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WFA, Boddeke HWGM, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, Aldape K. Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma[J]. Cancer Cell, 2013, 24:331-346. [5] Hu YH, Jiao BH, Wang CY, Wu JL. Regulation of temozolomide resistance in glioma cells via the RIP2/NF-κB/MGMT pathway[J]. CNS Neurosci Ther, 2021, 27:552-563. [6] Li JB, Tong LQ, Yi L, Liu PD, Xie Y, Wang XY, Yang XJ. ACT001 inhibits the neurosphere formation and stemness maintenance of U87-MG glioma stem cells through STAT3 signaling pathway[J]. Zhonghua Shen Jing Wai Ke Za Zhi, 2019, 35:1160-1166.[李佳博, 童鹿青, 易立, 刘沛东, 解杨, 王旭亚, 杨学军. ACT001通过STAT3信号通路抑制U87-MG胶质瘤干细胞的成球能力及干性维持的实验研究[J]. 中华神经外科杂志, 2019, 35:1160-1166.] [7] Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, Califano A, Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours[J]. Nature, 2010, 463:318-325. [8] Kim E, Kim M, Woo DH, Shin Y, Shin J, Chang N, Oh YT, Kim H, Rheey J, Nakano I, Lee C, Joo KM, Rich JN, Nam DH, Lee J. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells[J]. Cancer Cell, 2013, 23:839-852. [9] Lin L, Jou D, Wang Y, Ma H, Liu T, Fuchs J, Li PK, Lü J, Li C, Lin J. STAT3 as a potential therapeutic target in ALDH+ and CD44+/CD24+ stem cell-like pancreatic cancer cells[J]. Int J Oncol, 2016, 49:2265-2274. [10] Wang H, Tao Z, Feng M, Li X, Deng Z, Zhao G, Yin H, Pan T, Chen G, Feng Z, Li Y, Zhou Y. Dual PLK1 and STAT3 inhibition promotes glioblastoma cells apoptosis through MYC[J]. Biochem Biophys Res Commun, 2020, 533:368-375. [11] Hammerlindl H, Ravindran Menon D, Hammerlindl S, Emran AA, Torrano J, Sproesser K, Thakkar D, Xiao M, Atkinson VG, Gabrielli B, Haass NK, Herlyn M, Krepler C, Schaider H. Acetylsalicylic acid governs the effect of sorafenib in RAS-mutant cancers[J]. Clin Cancer Res, 2018, 24:1090-1102. [12] Zhao W, Sachsenmeier K, Zhang L, Sult E, Hollingsworth RE, Yang H. A new bliss independence model to analyze drug combination data[J]. J Biomol Screen, 2014, 19:817-821. [13] Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel Sauvé CE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH, Verhaak RGW. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment[J]. Cancer Cell, 2018, 33:152. [14] Zeng Y, Xiao HL, Guo QN. Progress in the mechanism of mesenchymal transformation in gliblastoma[J]. Zhen Duan Bing Li Xue Za Zhi, 2019, 26:533-538.[曾英, 肖华亮, 郭乔楠. 胶质母细胞瘤上皮间叶转化机制研究进展[J]. 诊断病理学杂志, 2019, 26:533-538.] [15] Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, Aldape K. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis[J]. Cancer Cell, 2006, 9:157-173. [16] Fan M, Pfeffer LM. The STAT3 and hypoxia pathways converge on Vasorin to promote stemness and glioblastoma tumorigenesis through Notch1 stabilization[J]. Stem Cell Investig, 2018, 5:35. Yi L, Guo GC, Li JB, Fan XG, Li T, Tong LQ, Liu PD, Wang [17] XY, Yuan F, Yu SQ, Huang Q, Yang XJ. IKBKE, a prognostic factor preferentially expressed in mesenchymal glioblastoma, modulates tumoral immunosuppression through the STAT3/PD-L1 pathway[J]. Clin Transl Med, 2020, 10:e130. Cheng W, Zhang C, Ren X, Jiang Y, Han S, Liu Y, Cai J, Li M, [18] Wang K, Liu Y, Hu H, Li Q, Yang P, Bao Z, Wu A. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma[J]. J Neurosurg, 2017, 126:249-259. |